Nuvectis Pharma (NVCT) Accounts Payables (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Accounts Payables data on file, last reported at $4.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 56.92% year-over-year to $4.7 million; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (up 56.92% YoY), and the FY2025 full-year result was $6.3 million, up 151.16% from the prior year.
• Accounts Payables retreated to $4.7 million in Q1 2026, from $6.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $6.4 million in Q3 2025 to a low of $1.3 million in Q1 2022.
• A 5-year average of $3.0 million and a median of $2.5 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables sank 35.25% in 2024 and soared 184.79% in 2025, its largest moves.
• Tracing NVCT's Accounts Payables over 5 years: stood at $2.9 million in 2022, then fell by 4.78% to $2.8 million in 2023, then decreased by 9.85% to $2.5 million in 2024, then jumped by 151.16% to $6.3 million in 2025, then declined by 25.17% to $4.7 million in 2026.
• Business Quant data shows NVCT's Accounts Payables at $4.7 million in Q1 2026, $6.3 million in Q4 2025, and $6.4 million in Q3 2025.